M2Gen® is an informatics solution company dedicated to advancing personalized medicine by using high quality tissue, clinical data and molecular technology to accelerate the discovery and delivery of personalized medicine. Using a rapid learning approach based on Moffitt's Total Cancer Care protocol, the goal of M2Gen is to accelerate the science of precision medicine by creating evidence and knowledge-based solutions that identify a patient's susceptibility to disease, predict how the patient will respond to a particular drug, and match patients to the best therapies for an optimal treatment outcome. M2Gen, along with Moffitt and 17 hospitals in a Consortium Network, has created a large, cancer-focused, biorepository linked to clinical and molecular data.
For more information on Total Cancer Care, please visit: http://moffitt.org/patient-services/total-cancer-care
M2Gen partners with pharmaceutical and biotech companies to:
- Use data to enhance trial design & enrollment for pharma
- Reduce "guess work" associated with drug development
- Enable development of companion diagnostics
- Position drugs for accelerated approvals
- Speed enrollment of trials
M2Gen partners with NCI-Designated Cancer Centers participating in the Oncology Research Information Exchange Network (ORIEN).
ORIEN is a unique research partnership among North America's top cancer centers that recognize collaboration and access to data are keys to cancer discovery. Through ORIEN, founders Moffitt Cancer Center in Tampa and the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus have agreed to use a standardized protocol (Total Cancer Care) to follow patients throughout their lifetime and share both clinical and molecular data from patients enrolled in the protocol to enhance discovery and create evidence of what is the most effective therapy for individual patients.
For more information on ORIEN, please visit: www.ORIENCancer.org